KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accounts Payables (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Accounts Payables for 17 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 1.07% to $4.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 billion through Dec 2025, up 1.07% year-over-year, with the annual reading at $4.2 billion for FY2025, 1.07% up from the prior year.
  • Accounts Payables hit $4.2 billion in Q4 2025 for Abbott Laboratories, up from $4.1 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.8 billion in Q1 2022 to a low of $4.0 billion in Q3 2023.
  • Historically, Accounts Payables has averaged $4.2 billion across 5 years, with a median of $4.2 billion in 2024.
  • Biggest five-year swings in Accounts Payables: increased 27.82% in 2021 and later fell 12.4% in 2023.
  • Year by year, Accounts Payables stood at $4.4 billion in 2021, then increased by 4.51% to $4.6 billion in 2022, then decreased by 6.77% to $4.3 billion in 2023, then dropped by 2.33% to $4.2 billion in 2024, then increased by 1.07% to $4.2 billion in 2025.
  • Business Quant data shows Accounts Payables for ABT at $4.2 billion in Q4 2025, $4.1 billion in Q3 2025, and $4.3 billion in Q2 2025.